1. Average warfarin dosage (mg/d) by CKD stages 1 and 2 (no/mild) versus stage 3 (moderate) versus stages 4 and 5 (severe) stratified by CYP2C9 and VKORC1 genotype.
Average warfarin dosage (mg/d) by CKD stages 1 and 2 (no/mild) versus stage 3 (moderate) versus stages 4 and 5 (severe) stratified by CYP2C9 and VKORC1 genotype. Least square means of back-transformed log-dosage adjusted for VKORC1-1173, CYP2C9, GFR, age, race, gender, BMI, vitamin K intake, alcohol, education, insurance, income, smoking, number of comorbid conditions, and concomitant therapy with CYP2C9 inhibitors and HMG-CoA inhibitors. Values given for a 60-yr-old white man with BMI 30, consuming two servings of vitamin K–rich foods per week, nondrinker, nonsmoker, with no other comorbid conditions, no CYP2C9 inhibitors or HMG-CoA reductase inhibitors. Wt, wild-type; v, variant. CYP2C9 variant genotype includes *2 and *3 alleles among European Americans and *2, *3, *5, *6, and *11 alleles among African Americans. Variant VKORC1-1173C/T includes TT or CT.
Nita A. Limdi et al. JASN 2009;20:
©2009 by American Society of Nephrology